Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa), also known as CD16a, is a type I transmembrane glycoprotein and a member of the immunoglobulin superfamily. It is primarily expressed on natural killer (NK) cells, macrophages, and monocytes, where it serves as a potent activating receptor for the Fc portion of IgG1 and IgG3 antibodies. The primary biological function of FcγRIIIa is to mediate antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, providing a critical link between the adaptive and innate immune systems. In clinical practice, FcγRIIIa is the key mediator of the anti-tumor activity of many therapeutic monoclonal antibodies, such as rituximab and trastuzumab. Genetic variations in the FCGR3A gene, specifically the V158F polymorphism, significantly impact the receptor's binding affinity for IgG and are used as biomarkers to predict clinical response to antibody-based therapies. Beyond oncology, FcγRIIIa is implicated in the pathogenesis of autoimmune diseases and the clearance of viral infections, making it a significant target for drug development aimed at either enhancing or modulating immune effector functions.
Facilitates antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis by bridging IgG-coated target cells with effector cells (e.g., NK cells, macrophages). Therapeutic antibodies or bispecific engagers bind to FcγRIIIa to trigger the release of cytotoxic granules and pro-inflammatory cytokines.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa) (FcγRIIIa).